人民财讯8月20日电，恒瑞医药（600276）8月20日晚间公告，公司拟使用自有资金以集中竞价交易方式 回购股份，本次回购股份拟用于A股员工持股计划，本次回购股份的资金总额不低于10亿元，不超过20 亿元，回购价格不超过90.85元/股。 ...

恒瑞医药（600276）(01276)发布公告，公司于2025年8月20日召开第九届董事会第十八次会议，审议通 过了《关于以自有闲置资金进行委托理财的议案》。为进一步提升公司资金的使用效率，在不影响公司 正常经营的前提下，公司拟使用最高额不超过人民币60亿元(含本数)的自有闲置资金进行委托理财。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，公司于2025年8月20日召开第九届董事会第十八次会议， 审议通过了《关于以自有闲置资金进行委托理财的议案》。为进一步提升公司资金的使用效率，在不影 响公司正常经营的前提下，公司拟使用最高额不超过人民币60亿元(含本数)的自有闲置资金进行委托理 财。 ...

Growth - SOTONG Development reported a net profit of 523 million yuan in the first half of the year, a year-on-year increase of 1568.52% [2] - Muyuan Foods achieved a net profit of 10.53 billion yuan, reflecting a year-on-year growth of 1169.77% [2] - Spring Autumn Electronics posted a net profit of 93.32 million yuan, up 248.44% year-on-year [2] - Baobian Electric's net profit reached 75.37 million yuan, marking a year-on-year increase of 230.76% [2] - Baiyun Airport reported a net profit of 750 million yuan, with a year-on-year growth of 71.32% [2] - Hengdian East Magnetic's net profit was 1.02 billion yuan, showing a year-on-year increase of 58.94% [2] - China XD Electric recorded a net profit of 598 million yuan, up 30.08% year-on-year [2] - Heng Rui Medicine achieved a net profit of 4.45 billion yuan, reflecting a year-on-year growth of 29.67% [2] - Yanjinpuzi reported a net profit of 373 million yuan, with a year-on-year increase of 16.7% [2] - Lizhu Group posted a net profit of 1.281 billion yuan, marking a year-on-year growth of 9.4% [2] Decline and Loss - Zhongheng Electric reported a net profit of 47.48 million yuan, a year-on-year decline of 30.19% [2] - Yonghui Supermarket experienced a net loss of 241 million yuan, transitioning from profit to loss year-on-year [2] - Wantai Biological Pharmacy reported a net loss of 144 million yuan, also transitioning from profit to loss year-on-year [2] - Jimin Health reported a net loss of 52.70 million yuan [2]

Core Insights - The company reported a revenue of approximately RMB 15.761 billion for the first half of 2025, representing a year-on-year growth of 15.9% [1] - Net profit attributable to shareholders was RMB 4.45 billion, reflecting a year-on-year increase of 29.7% [1] - Basic earnings per share were RMB 0.70 [1] Revenue Breakdown - The growth in revenue and profit was primarily driven by increased sales and licensing income from innovative drugs, which amounted to RMB 9.561 billion, a year-on-year increase of 26.8%, accounting for 60.7% of total revenue [1] - Sales revenue from innovative drugs reached RMB 7.57 billion [1] Innovative Drug Performance - Key innovative drugs such as Rivoceranib, Darsylin, and Henggrelizumab have effectively addressed unmet clinical needs, with strong clinical data gaining recognition from doctors and patients, leading to continued rapid revenue growth [1] - Earlier launched innovative drugs like Arixtra, Remimazolam, Pyrotinib, and Fluorouracil have expanded their application scope due to accumulating post-market research evidence and new indications, contributing to sales revenue [1] - Other innovative products like Apatinib, Sulfapyridine, and Hecuqipob have also seen growth during the reporting period [1] Licensing Income - The company recognized licensing income as a regular business activity, with significant payments received from Merck Sharp & Dohme (USD 200 million) and IDEAYA Biosciences (USD 75 million), further boosting operational performance [2] Generic Drug Performance - Although sales revenue from generic drugs included in centralized procurement experienced a slight decline, high-quality generic products such as Liposomal Bupivacaine and the first approved generic product of Albumin-bound Paclitaxel in the U.S. saw rapid revenue growth, leading to a slight overall increase in generic drug business revenue [2]

2025年上半年，恒瑞医药创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%，其中创新药 销售收入75.70亿元。此外，恒瑞医药研发投入38.71亿元，其中费用化研发投入32.28亿元。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月20日，恒瑞医药发布2025年上半年业绩报告。公告显 示，2025年上半年恒瑞医药实现营业收入157.61亿元，同比增长15.88%；归属于上市公司股东的净利润 为44.5亿元，同比增长29.67%；归属于上市公司股东的扣除非经常性损益的净利润为42.73亿元，同比 增长22.43%；经营性现金流净额43亿元，同比增长41.8%。 ...

恒瑞医药（600276）(01276)发布公告，其已于2025年8月20日举行的董事会会议上审议通过了员工持股 计划。员工持股计划有待公司股东会审议批准后方能生效。 ...

Group 1: Company Performance - Muyuan Foods reported a net profit of 10.53 billion yuan for the first half of 2025, a year-on-year increase of 1169.77% [1] - Weicai Technology achieved a net profit of 101 million yuan, reflecting an increase of 831.03% year-on-year [2] - Hengrui Medicine's net profit reached 4.45 billion yuan, up 29.67% compared to the previous year [3] - Kingsoft Office's net profit was 747 million yuan, showing a growth of 3.57% year-on-year [6] - Jimin Health reported a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year [10] Group 2: Revenue Growth - Muyuan Foods' revenue for the first half of 2025 was 76.46 billion yuan, a 34.46% increase year-on-year [1] - Weicai Technology's revenue reached 634 million yuan, growing by 47.53% year-on-year [2] - Hengrui Medicine's revenue was 15.76 billion yuan, marking a 15.88% increase year-on-year [3] - Kingsoft Office's revenue was 2.66 billion yuan, reflecting a growth of 10.12% year-on-year [6] Group 3: Corporate Actions - Hengrui Medicine plans to repurchase shares worth between 1 billion and 2 billion yuan for an employee stock ownership plan [3] - Tianwei Foods is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8][9] - Oriental Zirconium's chairman plans to reduce his holdings by up to 1.315 million shares, accounting for 0.17% of the total share capital [7]

格隆汇8月20日丨恒瑞医药(01276.HK)公告，公司董事会已于2025年8月20日举行的董事会会议上审议通 过了员工持股计划。员工持股计划有待公司股东会审议批准后方能生效。参加员工持股计划的员工总人 数预计不超过1,316人（不含预留份额），其中公司董事（不含独立董事）、监事、高级管理人员不超 过9人（不含预留份额）。 ...

Core Insights - The company reported a revenue of approximately RMB 15.761 billion for the first half of 2025, representing a year-on-year growth of 15.9% [1] - Net profit attributable to shareholders reached RMB 4.45 billion, marking a 29.7% increase compared to the same period last year [1] - Basic earnings per share were RMB 0.70 [1] Revenue and Profit Growth - The growth in revenue and profit was primarily driven by increased sales and licensing income from innovative drugs [1] - Sales and licensing income from innovative drugs amounted to RMB 9.561 billion, a 26.8% increase year-on-year, accounting for 60.7% of total revenue [1] - Innovative drug sales revenue was RMB 7.57 billion [1] Innovative Drug Performance - Key innovative drugs such as Rivoceranib, Darsylin, and Henggrelin have effectively addressed unmet clinical needs, gaining recognition from doctors and patients, leading to sustained revenue growth [1] - Earlier launched innovative drugs like Arixtra, Remimazolam, Pyrotinib, and Fluorouracil have expanded their application scope due to accumulating clinical evidence and new indications, contributing to sales growth [1] - Other innovative products like Apatinib, Sulfapyridine, and Hecolin also experienced growth during the reporting period [1] Future Growth Potential - Some innovative products have not yet fully realized their sales potential due to their recent market entry and lack of inclusion in medical insurance [1] - The company aims to promote the widespread use of new products and accelerate the commercialization of high-quality innovative products to drive stronger future growth [1] Licensing Income - Licensing income from external partnerships has become a significant component of the company's revenue, with the company receiving USD 200 million from Merck Sharp & Dohme and USD 75 million from IDEAYA Biosciences during the reporting period [2] - This licensing income has further contributed to the growth of operational performance metrics [2] Generic Drug Performance - Although sales revenue from generic drugs included in centralized procurement saw a slight decline, high-quality generic products like Liposomal Bupivacaine and the first approved generic product of Albumin-bound Paclitaxel in the U.S. achieved rapid sales growth [2] - Overall, the generic drug business revenue experienced a slight increase due to these factors [2]